Drug Search Results
More Filters [+]

Amonafide

Alternative Names: amonafide, as-1413
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/amonafide)

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Antisoma Research
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Amonafide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Myeloid Leukemia

Phase 2: Acute Myeloid Leukemia|Prostate Cancer|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACCEDE

P3

Terminated

Acute Myeloid Leukemia

2011-01-31

AS1413-C-101

P2

Unknown status

Acute Myeloid Leukemia

2010-09-01

NCT00715637

P3

Unknown status

Acute Myeloid Leukemia

2010-06-01

AIPC

P2

Completed

Prostate Cancer

2005-12-01

Recent News Events